Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers

[1]  G. Gerken,et al.  Increased frequencies of CD8+ T lymphocytes recognizing wild‐type p53‐derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma , 2006, International journal of cancer.

[2]  J. Gehl,et al.  Elevated serum level of YKL‐40 is an independent prognostic factor for poor survival in patients with metastatic melanoma , 2006, Cancer.

[3]  S. Aamdal,et al.  Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer , 2006, Cancer Immunology, Immunotherapy.

[4]  I. Christensen,et al.  Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Nielsen,et al.  Serum YKL-40, A New Prognostic Biomarker in Cancer Patients? , 2006, Cancer Epidemiology Biomarkers & Prevention.

[6]  G. Bepler,et al.  Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[7]  M. Ricote,et al.  Cell Cycle Control Related Proteins (p53, p21, and Rb) and Transforming Growth Factor β (TGFβ) in Benign and Carcinomatous (In Situ and Infiltrating) Human Breast: Implications in Malignant Transformations , 2006, Cancer investigation.

[8]  L. Jones,et al.  p53‐specific CD8+ T‐cell responses in individuals with cutaneous squamous cell carcinoma , 2005, The British journal of dermatology.

[9]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Berzofsky,et al.  Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  I. Svane,et al.  Phenotypic and Functional Characterization of Clinical Grade Dendritic Cells Generated from Patients with Advanced Breast Cancer for Therapeutic Vaccination , 2005, Scandinavian journal of immunology.

[12]  H. Johnsen,et al.  Vaccination with p53-peptide–pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study , 2004, Cancer Immunology, Immunotherapy.

[13]  Mads Hald Andersen,et al.  Identification of Novel Survivin-Derived CTL Epitopes with Different HLA-A-Restriction Profiles , 2004, Cancer biology & therapy.

[14]  Mads Hald Andersen,et al.  Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. , 2003, Seminars in cancer biology.

[15]  C. Figdor,et al.  Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  B. Jensen,et al.  High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  H. Putter,et al.  Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients , 2003, Cancer Gene Therapy.

[18]  H. Johnsen,et al.  Clinical application of dendritic cells in cancer vaccination therapy , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[19]  M. Grégoire,et al.  Optimizing dendritic cell–based anticancer immunotherapy: maturation state does have clinical impact , 2003, Cancer Immunology, Immunotherapy.

[20]  D. Purdie,et al.  Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine , 2003, Cancer Immunology, Immunotherapy.

[21]  J. Roth,et al.  Development of vaccines against self-antigens: the p53 paradigm. , 2003, Current opinion in drug discovery & development.

[22]  E. van Marck,et al.  Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer , 2003, International journal of cancer.

[23]  C. Figdor,et al.  Phenotypical and functional characterization of clinical-grade dendritic cells. , 2005, Methods in molecular medicine.

[24]  H. Nielsen,et al.  High serum YKL‐40 level after surgery for colorectal carcinoma is related to short survival , 2002, Cancer.

[25]  H. Ling,et al.  The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. , 2002, The Biochemical journal.

[26]  R. Steinman,et al.  Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. , 2002, Blood.

[27]  E. Appella,et al.  Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. , 2002, Cancer research.

[28]  M. Claesson,et al.  A HLA‐A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope , 2002, International journal of cancer.

[29]  S. H. van der Burg,et al.  Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  L. Pedersen,et al.  Specific killing of P53 mutated tumor cell lines by a cross‐reactive human HLA‐A2‐restricted P53‐specific CTL line , 2001, International journal of cancer.

[31]  A. Enk,et al.  A comparison of two types of dendritic cell as adjuvants for the induction of melanoma‐specific T‐cell responses in humans following intranodal injection , 2001, International journal of cancer.

[32]  S. Brunak,et al.  Identification and Design of p53‐Derived HLA‐A2‐Binding Peptides with Increased CTL Immunogenicity * , 2001, Scandinavian journal of immunology.

[33]  Dr C. D. L. Reid.  Dendritic cells and immunotherapy for malignant disease , 2001, British journal of haematology.

[34]  J. Becker,et al.  Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. , 2001, Cancer research.

[35]  S. Jee,et al.  Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency , 2001, Oncogene.

[36]  G. Schuler,et al.  A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. , 2000, Journal of immunological methods.

[37]  R. Nishimura,et al.  An Analysis of Serum Interleukin-6 Levels to Predict Benefits of Medroxyprogesterone Acetate in Advanced or Recurrent Breast Cancer , 2000, Oncology.

[38]  T. Soussi.  The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation , 2000, Annals of the New York Academy of Sciences.

[39]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[40]  Zeuthen,et al.  Cytotoxic T‐Lymphocyte Clones, Established by Stimulation with the HLA‐A2 Binding p5365–73 Wild Type Peptide Loaded on Dendritic Cells In Vitro, Specifically Recognize and Lyse HLA‐A2 Tumour Cells Overexpressing the p53 Protein , 2000, Scandinavian journal of immunology.

[41]  M. Christian,et al.  Measuring response in solid tumors: unidimensional versus bidimensional measurement. , 1999, Journal of the National Cancer Institute.

[42]  Guo‐Jun Zhang,et al.  Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. , 1999, Anticancer research.

[43]  G. Schuler,et al.  Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. , 1999, Journal of immunological methods.

[44]  J. Blay,et al.  Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. , 1998, Blood.

[45]  S. Chariyalertsak,et al.  Prognostic importance of p53 and c-erbB-2 oncoproteins overexpression in patients with breast cancer. , 1998, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[46]  J. O'dell,et al.  Chondrex: new marker of joint disease. , 1998, Clinical chemistry.

[47]  M. Theobald,et al.  Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes , 1997, The Journal of experimental medicine.

[48]  L. Fugger,et al.  Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Gabriella,et al.  Expression of and Response to lnie rleukin 6 (IL6) in Human Mammary Tumors1 , 2006 .

[50]  M. Mathieu,et al.  Primary proliferative T cell response to wild‐type p53 protein in patients with breast cancer , 1995, European journal of immunology.

[51]  S. Syrjänen,et al.  Implications of the p53 tumor-suppressor gene in clinical oncology. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  T. Kishimoto,et al.  The biology of interleukin-6. , 1989, Blood.

[53]  G. Dranoff,et al.  Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.

[54]  S. Lutzker,et al.  Use of dendritic cells to immunize against cancers overexpressing p53. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  D. Carbone,et al.  Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  Y. Morishita,et al.  Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report , 2000, Breast cancer.

[57]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.

[58]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[59]  Alessandro Sette,et al.  The optimization of helper T lymphocyte (HTL) function in vaccine development , 1998, Immunologic research.

[60]  M. Sherman,et al.  A Preliminary Report , 1953 .